Literature DB >> 36251137

Insulin Downregulates the Expression of ATP-binding Cassette Transporter A-I in Human Hepatoma Cell Line HepG2 in a FOXO1 and LXR Dependent Manner.

Vladimir S Shavva1, Anna V Babina1, Ekaterina V Nekrasova1, Alexey V Lisunov1,2, Ella B Dizhe1, Galina N Oleinikova1, Sergey V Orlov3,4.   

Abstract

ATP-binding cassette transporter A-I (ABCA1) is an ubiquitously expressed protein whose main function is the transmembrane transport of cholesterol and phospholipids. Synthesis of ABCA1 protein in liver is necessary for high-density lipoprotein (HDL) formation in mammals. Thus, the mechanism of ABCA1 gene expression regulation in hepatocytes are of critical importance. Recently, we have found the insulin-dependent downregulation of other key player in the HDL formation-apolipoprotein A-I gene (J. Cell. Biochem., 2017, 118:382-396). Nothing is known about the role of insulin in the regulation of ABCA1 gene. Here we show for the first time that insulin decreases the mRNA and protein levels of ABCA1 in human hepatoma cell line HepG2. PI3K, p38, MEK1/2, JNK and mTORC1 signaling pathways are involved in the insulin-mediated downregulation of human ABCA1 gene. Transcription factors LXRα, LXRβ, FOXO1 and NF-κB are important contributors to this process, while FOXA2 does not regulate ABCA1 gene expression. Insulin causes the decrease in FOXO1, LXRα and LXRβ binding to ABCA1 promoter, which is likely the cause of the decrease in the gene expression. Interestingly, the murine ABCA1 gene seems to be not regulated by insulin in hepatocytes (in vitro and in vivo). We suggest that the reason for this discrepancy is the difference in the 5'-regulatory regions of human and murine ABCA1 genes.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  ATP-binding cassette transporter A1; FOXO1; HepG2; LXRs; insulin; nuclear receptors

Year:  2022        PMID: 36251137     DOI: 10.1007/s12013-022-01109-w

Source DB:  PubMed          Journal:  Cell Biochem Biophys        ISSN: 1085-9195            Impact factor:   2.989


  32 in total

1.  The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease.

Authors:  M Bodzioch; E Orsó; J Klucken; T Langmann; A Böttcher; W Diederich; W Drobnik; S Barlage; C Büchler; M Porsch-Ozcürümez; W E Kaminski; H W Hahmann; K Oette; G Rothe; C Aslanidis; K J Lackner; G Schmitz
Journal:  Nat Genet       Date:  1999-08       Impact factor: 38.330

2.  Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency.

Authors:  A Brooks-Wilson; M Marcil; S M Clee; L H Zhang; K Roomp; M van Dam; L Yu; C Brewer; J A Collins; H O Molhuizen; O Loubser; B F Ouelette; K Fichter; K J Ashbourne-Excoffon; C W Sensen; S Scherer; S Mott; M Denis; D Martindale; J Frohlich; K Morgan; B Koop; S Pimstone; J J Kastelein; J Genest; M R Hayden
Journal:  Nat Genet       Date:  1999-08       Impact factor: 38.330

3.  High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease.

Authors:  H Bryan Brewer
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-03       Impact factor: 8.311

4.  Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1.

Authors:  S Rust; M Rosier; H Funke; J Real; Z Amoura; J C Piette; J F Deleuze; H B Brewer; N Duverger; P Denèfle; G Assmann
Journal:  Nat Genet       Date:  1999-08       Impact factor: 38.330

5.  Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I.

Authors:  Jenelle M Timmins; Ji-Young Lee; Elena Boudyguina; Kimberly D Kluckman; Liam R Brunham; Anny Mulya; Abraham K Gebre; Jonathan M Coutinho; Perry L Colvin; Thomas L Smith; Michael R Hayden; Nobuyo Maeda; John S Parks
Journal:  J Clin Invest       Date:  2005-04-07       Impact factor: 14.808

Review 6.  Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis.

Authors:  Anatol Kontush; M John Chapman
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

Review 7.  New insights into the regulation of HDL metabolism and reverse cholesterol transport.

Authors:  Gary F Lewis; Daniel J Rader
Journal:  Circ Res       Date:  2005-06-24       Impact factor: 17.367

8.  Specific binding of ApoA-I, enhanced cholesterol efflux, and altered plasma membrane morphology in cells expressing ABC1.

Authors:  N Wang; D L Silver; P Costet; A R Tall
Journal:  J Biol Chem       Date:  2000-10-20       Impact factor: 5.157

9.  Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1.

Authors:  Cheryl L Wellington; Liam R Brunham; Steven Zhou; Roshni R Singaraja; Henk Visscher; Allison Gelfer; Colin Ross; Erick James; Guoqing Liu; Mary T Huber; Yu-Zhou Yang; Robin J Parks; Albert Groen; Jamila Fruchart-Najib; Michael R Hayden
Journal:  J Lipid Res       Date:  2003-05-01       Impact factor: 5.922

10.  Tissue-specific roles of ABCA1 influence susceptibility to atherosclerosis.

Authors:  Liam R Brunham; Roshni R Singaraja; MyNgan Duong; Jenelle M Timmins; Catherine Fievet; Nagat Bissada; Martin H Kang; Amrit Samra; Jean-Charles Fruchart; Bruce McManus; Bart Staels; John S Parks; Michael R Hayden
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-02-05       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.